Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 14/20 | 0.65 |
| ▸ | NPC1 | O15118 | 13/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | EED | O75530 | 1/20 | 0.60 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.60 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.60 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.60 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.56 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856089 | 0.86 | HPGD (1.00) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL28704189 | 0.85 | HPGD (0.71) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL2605842 | 0.84 | POLB (0.69) | HPGDRAB9ANPC1POLB | |
| SCHEMBL10364571 | 0.84 | HPGD (0.55) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL10364983 | 0.84 | HPGD (0.55) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL2857896 | 0.84 | HPGD (0.77) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL10367090 | 0.84 | HPGD (0.72) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL2605690 | 0.81 | ALDH1A1 (0.74) | HPGDSMN1; SMN2POLB | |
| SCHEMBL10368553 | 0.81 | HPGD (0.52) | HPGDRAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL2860286 | 0.81 | RAB9A (0.87) | HPGDRAB9ANPC1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | HPGD 1051/4885RAB9A 1119/4885NPC1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.